









Markets
/
Stocks
/
nasdaq-mrna
/

Moderna Inc

MRNA

24.768USD

-1.112-4.30%

Market hours （ET）Quotes delayed by 15 min

9.63BMarket Cap

LossP/E TTM



Moderna Inc

24.768

-1.112-4.30%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-24

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. The company has shown average stock market performance, with mediocre fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

105 / 175

Overall Ranking

321 / 4718

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 25 analysts

Hold

Current Rating

46.445

Target Price

+80.09%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development. Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365), CMV vaccine (mRNA-1647), EBV vaccine (mRNA-1189 and mRNA-1195) and others.

Fairly Valued

The company’s latest PE is -3.45, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 310.55M shares, decreasing 3.31% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 41.62M shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-24

The company's current financial score is 5.77, which is lower than the Pharmaceuticals industry's average of 7.84. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 142.00M, representing a year-over-year decrease of 41.08%, while its net profit experienced a year-over-year decrease of 35.50%.

Score

Industry at a Glance

Previous score

5.75

Change



Financials

5.87

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.87

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.57

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.33

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.11

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-24

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is -3.39, which is -264.58% below the recent high of 5.58 and -113.20% above the recent low of -7.23.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 105/175

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-24

The company’s current earnings forecast score is 5.92, which is lower than the Pharmaceuticals industry's average of 7.78. The average price target for Moderna Inc is 31.00, with a high of 198.00 and a low of 15.00.

Score

Industry at a Glance

Previous score

5.92

Change

Support & Resistance

No Data

Analyst Rating

Based on 25 analysts

Hold

Current Rating

46.445

Target Price

+80.09%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

Moderna Inc

MRNA

Biogen Inc

BIIB

Amgen Inc

AMGN

Alnylam Pharmaceuticals Inc

ALNY

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-24

The company’s current price momentum score is 5.44, which is lower than the Pharmaceuticals industry's average of 6.84. Sideways: Currently, the stock price is trading between the resistance level at 27.77 and the support level at 23.15, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.29

Change

0.32

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.685

Neutral

RSI(14)

51.330

Neutral

STOCH(KDJ)(9,3,3)

70.689

Neutral

ATR(14)

1.359

High Vlolatility

CCI(14)

99.592

Neutral

Williams %R

31.122

Buy

TRIX(12,20)

-0.241

Sell

StochRSI(14)

45.485

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

25.784

Sell

MA10

25.154

Sell

MA20

24.824

Sell

MA50

27.360

Sell

MA100

27.386

Sell

MA200

30.951

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-24

The company’s current institutional recognition score is 7.00, which is higher than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 79.82%, representing a quarter-over-quarter decrease of 5.26%. The largest institutional shareholder is The Vanguard, holding a total of 41.62M shares, representing 10.70% of shares outstanding, with 2.45% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

40.25M

+0.18%

Baillie Gifford & Co.

Star Investors

24.95M

-35.85%

BlackRock Institutional Trust Company, N.A.

17.87M

-0.92%

Fidelity Management & Research Company LLC

20.83M

+13.30%

State Street Global Advisors (US)

17.78M

+1.15%

Two Sigma Investments, LP

8.26M

+976.22%

Boston Biotech Ventures, L.L.C.

9.21M

+1.77%

Geode Capital Management, L.L.C.

7.46M

+2.97%

Theleme Partners LLP

7.24M

-0.88%

D. E. Shaw & Co., L.P.

5.64M

+218.66%

Risk Assessment

Currency: USD Updated: 2025-09-24

The company’s current risk assessment score is 3.14, which is lower than the Pharmaceuticals industry's average of 4.07. The company's beta value is 2.00. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.